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Article
When understood as a wide concept encompassing physi-
cal health and emotional well-being, quality of life is a 
key aspect of chronic diseases. Sexual health is a state of 
physical, emotional, mental, and social well-being related 
to sexuality. Sexual functioning and quality of life are 
interwoven phenomena (Shamspour, Assari, & Lankarani, 
2010). In Human Immunodeficiency Virus (HIV) infec-
tion, sexual health has always been an issue of interest. 
Since the beginning of the epidemic, research has been 
conducted to determine the presence of sexual dysfunc-
tion in people living with HIV infection and to evaluate 
its prevalence and associated factors.
In the early 1990s, a relationship was established 
between HIV infection and higher risk of sexual dys-
function in men, especially ejaculatory problems (Jones, 
Klimes, & Catalan, 1994). Since then, prevalence val-
ues have been diverse but high, oscillating between 30% 
and 74% (Asboe et al., 2007; Cove & Petrak, 2004; 
Ende, Lo Re, DiNubile, & Mounzer, 2006; Lallemand, 
Salhi, Linard, Giami, & Rozenbaum, 2002; Moreno-
Pérez et al., 2010; Schrooten et al., 2001). There is now 
general agreement that sexual dysfunction is more pres-
ent in HIV-infected men than in non-HIV-infected men 
(Zona et al., 2012).
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Abstract
The prevalence and associated factors of erectile dysfunction (ED) in Human Immunodeficiency Virus (HIV)–infected 
men remain controversial. The authors evaluated ED, clinical, and emotional variables in a group of 501 HIV-infected 
men in a cross-sectional 4-month observational study. ED was assessed using the International Index of Erectile 
Function–5 and emotional status using the Hospital Anxiety and Depression (HAD) questionnaire. Median age 
(interquartile range) was 42 (35, 48) years. Time since HIV diagnosis was 6.3 (2.6, 17.1) years, 92% were taking 
antiretroviral treatment and 81.8% had an HIV-RNA viral load <50 copies. The prevalence of ED was 58.5%. ED 
was mild in 30.1%, mild to moderate in 19.5%, moderate in 6.1%, and severe in 2.5%. ED medications were used by 
19% of men. In the univariate analysis, the variables associated with all degrees of ED were older age, longer time 
since HIV diagnosis, higher scores in HAD, not taking efavirenz, taking etravirine, taking ritonavir, HIV/Hepatitis C 
Virus coinfection, and taking a protease inhibitor-containing regimen. For mild to moderate, moderate, and severe 
ED, the same variables were significant, as were lower nadir CD4 cell count, lower social support, taking atazanavir, 
concomitant conditions, and concomitant treatments. The variables that remained significant in the multivariate 
analyses, considering all degrees of ED or excluding mild ED were the following: older age and higher scores in HAD 
total. In summary, ED affected more than half of this cohort of well controlled HIV-infected men. Age and emotional 
status seemed to play a fundamental role in its presence.
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Discrepancies also arise with respect to associated fac-
tors. The findings of various studies suggested that sexual 
dysfunction is associated with the use of antiretroviral 
treatment (ART), specifically, protease inhibitors (PIs; 
Colson et al., 2002; Moreno-Pérez et al., 2010; Schrooten 
et al., 2001). However, this relationship remained contro-
versial, since other researchers reported contradictory 
data (Ende et al., 2006; Lallemand et al., 2002; Wang 
et al., 2013). Additional factors frequently mentioned 
include older age (Asboe et al., 2007; Guaraldi et al., 
2007; Moreno-Pérez et al., 2010; Pérez, Moreno, Navarro, 
Santos, & Palacios, 2013), duration of exposure to ART 
(Asboe et al., 2007; Moreno-Pérez et al., 2010), and emo-
tional disturbances and medications to treat them (Asboe 
et al., 2007; Guaraldi et al., 2007; Hart et al., 2012; Hart 
et al., 2015; Pérez et al., 2013). The objectives of this 
study were to evaluate erectile dysfunction (ED) in a 
wide sample of men and to explore sociodemographic, 
clinical, and emotional contributing factors.
Material and Method
The HIV-sex male study aims to evaluate the sexual 
activity of men living with HIV in Spain. This cross- 
sectional 4-month observational study was developed in a 
sample of men attending an HIV Unit in Badalona 
(Barcelona, Spain). Eligibility criteria included male 
birth sex, age ≥18 years and documented HIV infection. 
Concomitant pathologies or treatments were not exclu-
sion criteria. All men who attended the HIV Unit for their 
regular medical visits were approached in the waiting 
room. The procedures and objectives of the study were 
explained verbally and written information was given.
The men who agreed to participate provided their written 
consent and completed the study questionnaires. The Ethics 
Committee of Germans Trias i Pujol University Hospital 
approved the study (PI-13-067). Data were collected from 
November, 2013 to March, 2014. Participants whose data 
were incomplete were excluded from the analysis.
Main Outcome Measures
Demographic variables were self-reported and collected 
with a form developed ad hoc for the study. Data included 
age, country of birth, marital status, sexual orientation, 
serologic status of partner (if applicable), use of ED med-
ications in the past 15 days, and adherence to ART in the 
past 15 days (if applicable). Clinical variables were 
retrieved from medical records and clinical databases and 
included time since HIV diagnosis, current CD4 cell 
count, nadir CD4 cell count, highest HIV-RNA viral load, 
current HIV-RNA viral load, type of ART if applicable, 
concomitant conditions, and concomitant treatments.
ED was evaluated using the International Index of 
Erectile Function (IIEF-5) in its validated Spanish 
version (Martin-Morales et al., 2001; Rosen, Cappelleri, 
Smith, Lipsky, & Peña, 1999). The IIEF-5 is a brief, five-
item version of the IIEF. Scores are interpreted as fol-
lows: severe ED (5-7 points), moderate (8-11 points), 
mild to moderate (12-16 points), mild (17-21 points), and 
normal (22-25 points). Two outcome variables were 
defined: The first one comparing patients without ED and 
patients with any degree of ED and the second one com-
paring patients without ED or mild ED and patients with 
mild to moderate, moderate, and severe ED.
The symptoms of depression and anxiety were mea-
sured using the Hospital Anxiety and Depression Scale 
(HAD) in its validated Spanish version (Herrero et al., 
2003; Zigmond & Snaith, 1983). The HAD is a widely 
used 14-item self-report scale designed to briefly mea-
sure current anxiety and depressive symptoms in nonpsy-
chiatric hospital patients. Somatic symptoms are excluded 
to avoid confounding. Scores on each scale can be inter-
preted in ranges: normal (0-7), mild (8-10), moderate (11-
14), and severe (15-21). The authors consider a score of 
11 or higher to indicate probable caseness of mood disor-
der on the anxiety or depression subscales, and a score of 
8-10 as merely suggestive of a disorder (Snaith, 2003).
Finally, the Marlowe–Crowne Social Desirability 
Scale was included in its validated Spanish version (Ávila 
Espada & Tomé Rodriguez, 1989; Crowne & Marlowe, 
1960). This scale was designed to measure social desir-
ability independently of psychopathology. In other words, 
it assesses whether patients are responding truthfully or 
are misrepresenting themselves to manage their self- 
presentation. Scores are interpreted as follows: Low scor-
ers (0-8) are more willing to respond to the test truthfully, 
even when their answers might meet with social disap-
proval; average scorers (9-19) tend to identify an average 
degree of concern for the social desirability of their 
responses; and high scorers (20-33) are highly concerned 
about social approval and respond to test items in such a 
way as to avoid social disapproval.
Statistical Analyses
Continuous variables were analyzed using the Kolmogorov–
Smirnov test to assess for normal distribution. Due to the 
fact that these variables did not follow a normal distribu-
tion, they were expressed as median and interquartile range. 
Percentages (number of patients) were given for the dis-
crete variables.
To identify covariates that were independently associated 
with different stages of ED, stepwise logistic regression was 
used. The multivariate models included all covariates asso-
ciated with ED at the level of p ≤ .25 in the univariate analy-
sis, as well as those hypothesized to be associated with ED 
regardless of statistical significance. Furthermore, the cor-
relation of continuous variables was taken into account to 
avoid multicollinearity. The statistical analyses were 
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performed using SPSS 15.0 (SPSS Inc., Chicago, IL, USA), 
assuming a 95% confidence level and two-tailed tests.
Results
The study was proposed to a total of 521 men. Eight men 
refused to participate and 12 returned the questionnaires 
uncompleted. Thus, the final sample comprised 501 men. 
The demographic and clinical characteristics of the study 
sample are reported in Table 1.
Median age (interquartile range) was 42 (35, 48) years. 
Two hundred and forty-one (48.1%) of the men were 
married or had a stable partner (≥6 months), 93 (18.6%) 
of whom were also infected with HIV. Sexual intercourse 
was with men only in 380 (75.8%) participants. Median 
time since HIV diagnosis was 6.3 (2.6, 17.1) years, and 
461 (92%) men were taking ART. Of these, 178 (38.6%) 
took a PI-containing regimen, 154 (33.4%) a nonnucleo-
side reverse transcriptase inhibitor–containing regimen, 
and 83 (18%) an integrase strand transfer inhibitor–con-
taining regimen. The most common antiretroviral drugs 
were tenofovir (275 men, 59.6%), emtricitabine (272, 
59%), ritonavir (201, 43.6%), darunavir (149, 32.3%), 
lamivudine (99, 21.4%), abacavir (95, 20.6%), raltegravir 
(83, 18%), and efavirenz (65, 14%).
Undetectable HIV-RNA viral load was present in 410 
(81.8%) participants, and 429 (93%) adhered to ≥95% of 
their ART. Ninety (18%) individuals were coinfected 
Table 1. Characteristics of the Study Sample.
Total (N = 501) Patients without ED (N = 208) Patients with ED (N = 293)
Age, years 42 (35, 48) 38 (32, 45) 45 (36, 50)
Country of birth, %
 Spain 73.3 72.6 73.7
 Others 26.7 27.4 26.3
Marital status, %
 Single 45.1 46.1 44.4
 Married or stable partner 48.1 48.6 47.8
 Divorced 6 5.3 6.5
 Widow 0.6 — 1.3
Sexual intercourse, %
 Only with men 75.8 76.9 75.1
 Only with women 19.2 17.8 20.1
 With men and women 5 5.3 4.7
Partner infected with HIV, % 18.6 18.8 18.4
Time since HIV diagnosis, years 6.3 (2.6, 17.1) 4.7 (1.8, 13.3) 7.5 (3, 18.4)
On ART, % 92 91.3 92.5
Type of ART, %
 NNRTI 33.4 40.4 28.5
 PI 38.6 33.5 42.1
 INSTI 18 18 17.9
 INSTI + PI 3.9 4.2 3.6
 CCR5 blockers + PI 1.5 0.5 0.7
 Other combinations 4.6 3.3 5.4
CD4 cell count, cells/µL 617 (465, 815) 631 (480, 832) 597 (451, 811)
Nadir CD4 cell count, cells/µL 300 (190, 416) 315 (217, 431) 287 (174, 412)
Highest viral load, copies/mL 71.000 (13.000, 240.000) 65.500 (15.000, 220.000) 75.000 (12.235, 248.953)
Undetectable viral load, %a 81.7 81.9 81.3
Coinfection with HCV, % 18 12.5 21.8
Concomitant pathologies, % 44.5 39.4 48.1
Use of ED medications, % 19 11.1 24.6
HAD total 11 (6, 16) 8 (4, 12) 12 (8, 17)
HAD anxiety 7 (4, 10) 6 (3, 8) 8 (5, 11)
HAD depression 4 (1, 6) 2 (1, 4) 4 (2, 7)
Adherence to ART, %b 97.1 97.1 97.3
Note. HAD = Hospital Anxiety and Depression Scale; HCV = hepatitis C virus; ART = antiretroviral therapy; NNRTI = nonnucleoside reverse 
transcriptase inhibitors; PI = protease inhibitors; INSTI = integrase strand transfer inhibitors; ED = erectile dysfunction. Data expressed as 
median (interquartile range), except when indicated otherwise.
aUndetectable at ≤50 copies/mL level. bNumber of patients reporting ≥95% of ART medication intake in the past 15 days.
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with Hepatitis C Virus (HCV) and 223 (44.5%) had one 
or more concomitant conditions, the most frequent being 
metabolic disorders (17.2%) and rheumatic and musculo-
skeletal disorders (13%). Concomitant treatments were 
taken by 182 (36.3%) men.
According to the IIEF-5, the prevalence of all degrees 
of ED was 58.5% (293 men). In this group, the degree of 
ED was mild in 151 men (51.5%), mild to moderate in 98 
(33.4%), moderate in 31 (10.5%), and severe in 13 (4.4%). 
ED medications (mainly tadalafil and sildenafil citrate) 
had been used in the past 15 days by 95 (19%) men. Among 
the group of men who had taken ED medications, 24 
(25.2%) of them did not report ED, but the rest still reported 
ED that was mostly mild or mild to moderate.
The HAD total score was 11 (6, 16), with a HAD anxi-
ety subscale of 7 (4, 10) and a HAD depression subscale 
of 4 (1, 6). These results were within the normal range. 
The Marlowe–Crowne Social Desirability Scale was 18 
(13, 21). Twenty-three (4.6%) men were low scorers, 313 
(62.5%) were average scorers, and 162 (32.3%) were 
high scorers.
Univariate and Multivariate Regression 
Analyses Considering Any Degree of ED
As seen in Table 2, the variables associated with any 
degree of ED in the univariate analysis were as follows: 
older age, longer time since HIV diagnosis (years), higher 
scores in HAD total, higher scores in HAD anxiety, 
higher scores in HAD depression, not taking efavirenz, 
taking etravirine, taking ritonavir, HIV/HCV coinfection, 
and taking a PI-containing regimen. In the multivariate 
regression analysis, only older age and higher scores in 
HAD total remained associated with ED.
Univariate and Multivariate Regression 
Analyses Considering Mild to Moderate, 
Moderate, and Severe ED
In the univariate analysis, the associated variables were 
older age, longer time since HIV diagnosis (years), lower 
nadir CD4 cell count, higher scores in HAD total, higher 
scores in HAD anxiety, higher scores in HAD depression, 
lower social support, not taking efavirenz, taking etra-
virine, taking atazanavir, taking ritonavir, HIV/HCV 
coinfection, having concomitant conditions, taking con-
comitant treatments, and taking a PI-containing regimen. 
In the multivariate analysis, older age and higher scores 
in HAD total remained associated with mild to moderate, 
moderate, and severe ED (Table 3). The findings in both 
multivariate models were the same when the authors con-
sidered all degrees of ED or only mild to moderate, mod-
erate, and severe ED.
Discussion
The current results identify that ED affected more than 
half of this cohort of well controlled HIV-infected men. 
Age and emotional status seemed to play a fundamental 
role in its presence. The term sexual dysfunction encom-
passes ED, loss of libido, and difficulty achieving orgasm. 
In HIV infection, several studies have pointed to the exis-
tence of difficulties in all three areas (Jones et al., 1994; 
Lamba, Goldmeier, Mackie, & Scullard, 2004), although 
ED is the field that has generated most research. Rates of 
ED in HIV-infected men have oscillated considerably, 
probably owing to the heterogeneity of the samples eval-
uated. However, numbers have always been high and 
have even reached 74% (Ende et al., 2006).
Table 2. Variables Associated With all Degrees of ED.
Covariate
Univariate regression Multivariate regression
OR 95% CI p OR 95% CI p
Older age 1.059 [1.038, 1.080] <.001 1.059 [1.037, 1.08] <.001
Longer time since HIV diagnosis 1.032 [1.010, 1.054] .004 — — —
HAD total 1.111 [1.077, 1.147] <.001 1.112 [1.076, 1.148] <.001
HAD anxiety 1.159 [1.102, 1.221] <.001 — — —
HAD depression 1.234 [1.158, 1.316] <.001 — — —
Not taking efavirenz 2.289 [1.343, 3.904] .002 — — —
Taking etravirine 6.211 [1.421, 27.021] .015  
Taking ritonavir 1.519 [1.042, 2.221] .031 — — —
HIV/HCV coinfection 1.945 [1.182, 3.195] .009 — — —
Use of a PI-containing regimen 1.473 [1, 2.172] .050 — — —
Note. OR = odds ratio; CI = confidence interval; ED = erectile dysfunction; HIV = human immunodeficiency virus; HAD = Hospital Anxiety and 
Depression Scale; HCV = hepatitis C virus; PI = protease inhibitor; ART = antiretroviral therapy. The univariate analysis included the following 
variables: age, country of birth, marital status, sexual orientation, partner with HIV infection, time since HIV diagnosis, being on ARV, type of 
ARV (families and drugs), current CD4 cell count, nadir CD4 cell count, current HIV-RNA viral load, highest HIV-RNA viral load, HIV/HCV 
coinfection, presence of concomitant pathologies (and types), presence of concomitant treatments (and types), use of ED medications, HAD 
total, HAD anxiety, HAD depression, adherence to ARV, social desirability.
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In the current study, ED affected more than half of the 
sample, and although the degree was mild in 51.5% of the 
men interviewed, mild to moderate ED was present in 33.4%, 
and moderate and severe ED in 15%. The current results 
coincide with those of the other Spanish observational study 
performed to investigate ED in HIV-infected men (Pérez 
et al., 2013), in which ED was reported by 67% of the partici-
pants. The characteristics of the patients assessed in both 
studies were also similar, namely, the men were young, in 
their 40s, with good immunological and virological status. 
Accordingly, the authors believe that the results obtained in 
the large sample of 501 participants reinforce the data 
reported by Pérez et al. (2013) and highlight the magnitude of 
the problem. The current study also provides us with new 
data about the role of other associated factors.
Several variables were associated with ED in the uni-
variate analyses, although they did not reach significance in 
the multivariate models. Most of these variables were clini-
cal, namely, longer time since HIV diagnosis, lower nadir 
CD4 cell count, and existence of concomitant conditions 
and their treatments. It could be hypothesized that behind 
this information could be found, the profile of a long-term 
diagnosed and treated patient in whom ED might be another 
manifestation of the delicate physical and emotional situa-
tion described in previous studies (Coyne et al., 2010; 
Fumaz et al., 2012; Gonzalez-Garcia et al., 2014).
Although the use of PI-containing regimens were not 
significant in the multivariate analyses, it is worth mention-
ing its contribution in the univariate analyses in light of past 
controversies. Studies that reported a role for PIs in ED 
were based on drugs not currently used or that were used at 
higher doses (Colson et al., 2002; Schrooten et al., 2001). In 
the current study, the PIs taken by the participants were the 
most recently developed and widely used in the past few 
years. Therefore, more research is necessary to ascertain 
whether this new generation of PIs still contributes to ED.
Only two variables remained strongly associated with 
ED in the multivariate models, namely, older age and HAD 
total (a summary of anxiety and depression levels). Of note, 
the authors obtained the same information in the two multi-
variate models performed, when all degrees of ED were 
considered and when the authors considered only higher 
degrees of ED. Other authors included age in their list of 
relevant variables when discussing ED in HIV infection 
(Asboe et al., 2007; Moreno-Pérez et al., 2010; Pérez et al., 
2013). In the current study, age is particularly relevant, 
since the patients were relatively young (early 40s). 
Therefore, the impairment in sexual functioning might 
affect HIV-infected men both more often (Zona et al., 2012) 
and earlier, as with other typical manifestations of aging.
Although rates of anxiety and depression were low in 
the participants, poorer emotional status was another con-
tributing factor for ED. This finding is concordant with 
those reported elsewhere (Asboe et al., 2007; Guaraldi 
et al., 2007; Guaraldi et al., 2012; Pérez et al., 2013) and 
emphasizes the idea that the emotional status of patients 
who complain about sexual dysfunction should always be 
contemplated in their assessment. Also, considering that 
ED medications do not work in absence of sexual stimula-
tion, one could hypothesize that emotional status might 
partly explain the lack of efficacy of these drugs in the par-
ticipants who had taken them. Only 25% of the participants 
referred absence of ED, while the others still had symp-
toms that were mostly mild or mild to moderate. However, 
Table 3. Variables Associated With Mild to Moderate, Moderate, and Severe ED.
Covariate
Univariate regression Multivariate regression
OR 95% CI p OR 95% CI p
Older age 1.067 [1.043, 1.091] <.001 0.057 [1.037, 1.081] <.001
Longer time since HIV diagnosis (years) 1.049 [1.027, 1.073] <.001 — — —
Lower nadir CD4 cell count 1.001 [1, 1.002] .013  
Higher scores in HAD total 1.087 [1.055, 1.119] <.001 0.106 [1.076, 1.148] <.001
Higher scores in HAD anxiety 1.121 [1.066, 1.179] <.001 — — —
Higher scores in HAD depression 1.187 [1.121, 1.257] <.001 — — —
Lower social support 1.167 [1.018, 1.338] .027  
Not taking efavirenz 2.255 [1.140, 4.461] .020 — — —
Taking etravirine 7.407 [2.611, 20.831] <.001  
Taking atazanavir 2.618 [1.316, 5.211] .006  
Taking ritonavir 1.883 [1.251, 2.821] .002 — — —
HIV/HCV coinfection 1.802 [1.121, 2.907] .016 — — —
Having concomitant conditions 1.941 [1.309, 2.873] .001  
Taking concomitant treatments 2.049 [1.379, 3.051] <.001  
Use of PI-containing regimen 1.684 [1.112, 2.529] .012 — — —
Note. OR = odds ratio; CI = confidence interval; ED = erectile dysfunction; HIV = human immunodeficiency virus; HAD = Hospital Anxiety and 
Depression Scale; HCV = hepatitis C virus; PI = protease inhibitor.
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this low rate of efficacy of ED medications merits further 
research to ascertain other contributing factors.
The current findings are subject to a series of limita-
tions. All data are self-reported, potentially leading to 
underreporting of socially undesirable behaviors. Sexual 
dysfunction is still a delicate topic for some people. 
Therefore, the authors decided to include a questionnaire 
that provided information on social desirability. Since no 
differences were identified between the presence of ED 
and the degree of social desirability, the authors believe 
that most of the participants were sincere in their responses.
It should also be taken into account that in the current 
study, ED was only determined through self-report. It is 
recommendable to establish ED diagnosis after a com-
plete physical and psychological evaluation to determine 
vasculogenic or psychogenic factors (Cavallini, 2016; 
Kellesarian et al., 2016). This study was motivated after 
the complaints observed in the clinical practice about ED. 
Thus, the authors were especially interested in knowing 
patients’ perception about it.
Another limitation is that the current study lacks a con-
trol group formed by HIV-noninfected participants with 
similar sociodemographic characteristics. The presence of 
a control group always provides more robust value to the 
findings. Also, the IIEF was used to asses ED. This ques-
tionnaire was constructed and validated in heterosexual 
men and a modified IIEF for men who have sex with men 
exists (Coyne et al., 2010). The IIEF was used because all 
men who attended the HIV unit, regardless of their sexual 
preference were included. One of the researchers was 
always available to answer any doubts when patients 
answered the questionnaires. Previous studies have suc-
cessfully evaluated ED with the IIEF in groups formed by 
heterosexual men and men who have sex with men 
(Romero-Velez et al., 2014). For all these reasons, the 
authors believe that the current data are reliable.
The analysis of additional clinical parameters such as 
serum testosterone or estradiol levels were not included. 
Although some studies reported a relationship between 
these parameters and ED in HIV-infected men (Lamba 
et al., 2004), others did not (Ende et al., 2006, Rochira 
et al., 2011). Therefore, further research should be per-
formed to clarify this discrepancy. The current study did 
not include the assessment of smoking either. Cigarette 
smoking is associated with ED in the general population 
(Kovac, Labbate, Ramasamy, Tang, & Lipshultz, 2015) 
and prevalence of smoking continues to be very high 
among HIV-infected people (Parks, Hernandez-Ramirez, 
Silverberg, Crothers, & Dubrow, 2016). Nevertheless, in 
a previous study smoking duration was related to ED only 
in HIV-negative men (Hart et al., 2015). More studies 
should be developed to evaluate better this variable in 
men with HIV infection. Finally, almost all the study 
patients had met the objectives of HIV treatment, namely, 
they were on ART and virologically suppressed. However, 
in patients with ED, this prevents us from distinguishing 
between the role of ART and the impact of the chronic 
inflammation caused by the virus itself.
One of the strengths of this study is its large and varied 
sample (501 participants). It assessed an extensive list of 
sociodemographic, clinical, and emotional variables as 
well. These also included parameters that have been consid-
ered controversial in the past, such as antiretroviral drugs.
Conclusions
The current study identifies that many men living with 
HIV infection experience mild to moderate ED and that 
this is related to older age and emotional disturbances. 
Considering the negative impact of sexual dysfunctions 
on quality of life, sexual health should be included in the 
regular assessment of men living with HIV infection. The 
health professional should try to facilitate an environment 
of trust, free of judgment.
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